Posted: 1 June 2023
Firebrick Pharma is pleased to provide an update on the progress of the confirmatory Phase 3 clinical trial of Nasodine Nasal Spray as a treatment for the common cold.
The study, which commences in 2022, aims to recruit 196 subjects with early-stage colds who are confirmed by PCR to have a viral infection (other than SARA-Cov-2). These subjects represent the primary endpoint population for the trial, referred to as the ITTi. At 30 May 2023, 160 ITTi subjects have been enrolled representing 82% of the final recruitment target.
In 2022, the trial ran for 26 weeks from 3 May 2022 to 31 October 2022 and recruited 223 subjects with colds (8.7 per week), of whom 45% (100) were virus-positive. The trial was then paused over the summer period and reopened on 21 March 2023.
In the 10 weeks since it re-opened, another 113 subjects have already been enrolled (11.3 per week), of whom 53% are virus-positive (60), bringing the total ITTi subjects to 160.
“Both the overall recruitment rate and the virus-positivity rate are significantly higher than we achieved in 2022,” said Dr Peter Molloy, Executive Chairman of Firebrick. “As a result, the weekly ITTi recruitment has gone up from 3.9 subjects in 2022 to 6.0 subjects in 2023, an increase of 55%.”
“We are now very confident about reaching out target of 196 subjects well before the end of the current cold season,” said Dr Molloy. “As previously telegraphed we expect to announce headline results during the third quarter.”
The trial results will be used primarily to support international regulatory fillings for Nasodine, including a European approval submission.
